{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:20:21Z","timestamp":1791948021810,"version":"4.3.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Neoantigen-based adoptive T cell therapies (ACTs) represent a promising avenue in cancer immunotherapy due to their exquisite tumor specificity. The first cell-based immunotherapy for a solid tumor, comprising tumor-infiltrating lymphocytes, recently received FDA approval. Building on this, we designed a distinct ACT approach, where T cell responses against personalized neoantigens are systematically generated from autologous peripheral blood. Here we report the establishment of NEO-STIM, an ex vivo induction process to prime and expand pre-existing memory and de novo CD8\n                    <jats:sup>+<\/jats:sup>\n                    and CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cell responses, thereby highlighting critical parameters for generating potent neoantigen-specific T cell responses. The drug products comprise mutant-reactive, polyfunctional, and cytotoxic CD8\n                    <jats:sup>+<\/jats:sup>\n                    and CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cells, able to recognize autologous tumor material. Following infusion, T cell responses are detected in tumor and blood of a patient, and display activated\/exhausted and cytotoxic phenotypes. A first-in-human clinical trial (NCT04625205) recently further validated proof-of-concept, supporting continued development of this ACT approach.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-68680-1","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T13:27:55Z","timestamp":1770298075000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["NEO-STIM advances personalized neoantigen-specific adoptive T cell therapy"],"prefix":"10.1038","volume":"17","author":[{"given":"Divya","family":"Lenkala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Kohler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7167-581X","authenticated-orcid":false,"given":"Noor A. M.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2972-4139","authenticated-orcid":false,"given":"Emily K.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joong Hyuk F.","family":"Sheen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Hannes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Esaulova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1117-8417","authenticated-orcid":false,"given":"Claudia","family":"Gottstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Attanasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavian D.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1823-9680","authenticated-orcid":false,"given":"Sebastian","family":"Hymson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirisha","family":"Meda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike","family":"van Zon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Scheij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhianne","family":"Voogd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1416-0529","authenticated-orcid":false,"given":"Brenda","family":"Raud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6478-7821","authenticated-orcid":false,"given":"Jessica S. W.","family":"Borgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maartje W.","family":"Rohaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen N.","family":"Balogh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9118-1051","authenticated-orcid":false,"given":"Asaf","family":"Poran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse Z.","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Srouji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram R.","family":"Juneja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina M.","family":"Arieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia M.","family":"Nijenhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastiaan","family":"Nuijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"DeMario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelledy","family":"Manson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0517-8804","authenticated-orcid":false,"given":"Ton N. M.","family":"Schumacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Gaynor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5884-7704","authenticated-orcid":false,"given":"John B.","family":"Haanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost H.","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1615-1087","authenticated-orcid":false,"given":"Marit M.","family":"van Buuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"68680_CR1","unstructured":"FDA. Approved Blood products - AMTAGVI https:\/\/www.fda.gov\/vaccines-blood-biologics\/approved-blood-products\/amtagvi (2024)."},{"key":"68680_CR2","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1182\/bloodadvances.2021006831","volume":"6","author":"H Kinoshita","year":"2022","unstructured":"Kinoshita, H. et al. Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT. Blood Adv. 6, 2520\u20132534 (2022).","journal-title":"Blood Adv."},{"key":"68680_CR3","doi-asserted-by":"crossref","unstructured":"Vasileiou, S. et al. T-cell therapy for lymphoma using non-engineered multiantigen-targeted T cells is safe and produces durable clinical effects. J. Clin. Oncol. 39, 1415\u20131425 (2021).","DOI":"10.1200\/JCO.20.02224"},{"key":"68680_CR4","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","volume":"17","author":"SA Rosenberg","year":"2011","unstructured":"Rosenberg, S. A. et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17, 4550\u20134557 (2011).","journal-title":"Clin. Cancer Res."},{"key":"68680_CR5","doi-asserted-by":"crossref","unstructured":"Klobuch, S., Seijkens, T. T. P., Schumacher, T. N. & Haanen, J. Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma. Nat. Rev. Clin. 21, 173\u2013184 (2024).","DOI":"10.1038\/s41571-023-00848-w"},{"key":"68680_CR6","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","volume":"387","author":"MW Rohaan","year":"2022","unstructured":"Rohaan, M. W. et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N. Engl. J. Med 387, 2113\u20132125 (2022).","journal-title":"N. Engl. J. Med"},{"key":"68680_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000848","volume":"8","author":"JH Van Den Berg","year":"2020","unstructured":"Van Den Berg, J. H. et al. Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up. J. Immunother. Cancer 8, e000848 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"68680_CR8","doi-asserted-by":"publisher","unstructured":"Khateb, M. et al. Rapid enrichment of progenitor exhausted neoantigen-specific CD8 T cells from peripheral blood. bioRxiv https:\/\/doi.org\/10.1101\/2025.05.11.653315 (2025).","DOI":"10.1101\/2025.05.11.653315"},{"key":"68680_CR9","unstructured":"Kristensen, N. P. et al. Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma. J. of Clin. Invest. 132, e150535 (2022)."},{"key":"68680_CR10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nm.3773","volume":"21","author":"C Linnemann","year":"2015","unstructured":"Linnemann, C. et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat. Med 21, 81\u201385 (2015).","journal-title":"Nat. Med"},{"key":"68680_CR11","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1158\/2159-8290.CD-18-1494","volume":"9","author":"MR Parkhurst","year":"2019","unstructured":"Parkhurst, M. R. et al. Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers. Cancer Discov. 9, 1022\u20131035 (2019).","journal-title":"Cancer Discov."},{"key":"68680_CR12","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/nm.3161","volume":"19","author":"PF Robbins","year":"2013","unstructured":"Robbins, P. F. et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19, 747\u2013752 (2013).","journal-title":"Nat. Med."},{"key":"68680_CR13","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1126\/science.aad1253","volume":"350","author":"E Tran","year":"2015","unstructured":"Tran, E. et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 350, 1387\u20131390 (2015).","journal-title":"Science"},{"key":"68680_CR14","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non\u2013small cell lung cancer. Science 348, 124\u2013128 (2015).","journal-title":"Science"},{"key":"68680_CR15","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1016\/j.ccell.2023.11.005","volume":"41","author":"R Yossef","year":"2023","unstructured":"Yossef, R. et al. Phenotypic signatures of circulating neoantigen-reactive CD8(+) T cells in patients with metastatic cancers. Cancer Cell 41, 2154\u20132165.e2155 (2023).","journal-title":"Cancer Cell"},{"key":"68680_CR16","doi-asserted-by":"crossref","unstructured":"Yarchoan, M. J.B.R., Lutz, E.R., Laheru, D.A., Jaffee, E.M. Targeting neoantigens to augment antitumour immunity - PubMed. Nat. Rev. Cancer 17, 209\u2013222 (2017).","DOI":"10.1038\/nrc.2016.154"},{"key":"68680_CR17","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1089\/hum.2012.030","volume":"23","author":"KM Kaluza","year":"2012","unstructured":"Kaluza, K. M. et al. Adoptive transfer of cytotoxic T lymphocytes targeting two different antigens limits antigen loss and tumor escape. Hum. Gene Ther. 23, 1054\u20131064 (2012).","journal-title":"Hum. Gene Ther."},{"key":"68680_CR18","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41586-019-1671-8","volume":"574","author":"E Alspach","year":"2019","unstructured":"Alspach, E. et al. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature 574, 696\u2013701 (2019).","journal-title":"Nature"},{"key":"68680_CR19","doi-asserted-by":"crossref","unstructured":"Espinosa-Carrasco, G. et al. Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors. Cancer Cell 42, 1202\u20131216 (2024).","DOI":"10.1016\/j.ccell.2024.05.025"},{"key":"68680_CR20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","volume":"183","author":"PA Ott","year":"2020","unstructured":"Ott, P. A. et al. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell 183, 347\u2013362 (2020).","journal-title":"Cell"},{"key":"68680_CR21","doi-asserted-by":"crossref","unstructured":"Fan, T. et al. Therapeutic cancer vaccines: advancements, challenges and prospects. Signal Transduction Target. Ther. 8, 450 (2023).","DOI":"10.1038\/s41392-023-01674-3"},{"key":"68680_CR22","doi-asserted-by":"crossref","unstructured":"Fritsch, E. F. et al. HLA-binding properties of tumor neoepitopes in humans. Cancer Immunol. Res. 2, 522 (2014).","DOI":"10.1158\/2326-6066.CIR-13-0227"},{"key":"68680_CR23","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1084\/jem.190.5.705","volume":"190","author":"MJ Pittet","year":"1999","unstructured":"Pittet, M. J. et al. High frequencies of naive Melan-a\/Mart-1\u2013specific Cd8+ T cells in a large proportion of human histocompatibility leukocyte antigen (Hla)-A2 individuals. J. Exp. Med. 190, 705\u2013716 (1999).","journal-title":"J. Exp. Med."},{"key":"68680_CR24","doi-asserted-by":"crossref","unstructured":"van Buuren, M. M., Calis, J. J. & Schumacher, T. N. High sensitivity of cancer exome-based CD8 T cell neo-antigen identification. Oncoimmunology 3, e28836 (2014).","DOI":"10.4161\/onci.28836"},{"key":"68680_CR25","doi-asserted-by":"crossref","unstructured":"Vocanson M, et al. Human T cell priming assay: depletion of peripheral blood lymphocytes in CD25(+) cells improves the in vitro detection of weak allergen-specific T cells. Experientia supplementum 104, 89\u2013100 (2014).","DOI":"10.1007\/978-3-0348-0726-5_7"},{"key":"68680_CR26","doi-asserted-by":"crossref","unstructured":"Raber, P. L. et al. T cells conditioned with MDSC show an increased anti-tumour activity after adoptive T cell-based immunotherapy. Oncotarget 7, 17565\u201317578 (2016).","DOI":"10.18632\/oncotarget.8197"},{"key":"68680_CR27","doi-asserted-by":"crossref","unstructured":"Srivastava, M. K., Sinha, P., Clements, V. K., Rodriguez, P. & Ostrand, R. S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 70, 68\u201377 (2010).","DOI":"10.1158\/0008-5472.CAN-09-2587"},{"key":"68680_CR28","first-page":"175883592211071","volume":"14","author":"V Hoyos","year":"2022","unstructured":"Hoyos, V. et al. Multi-antigen-targeted T-cell therapy to treat patients with relapsed\/refractory breast cancer. Therapeutic Adv. Med. Oncol. 14, 17588359221107113 (2022).","journal-title":"Therapeutic Adv. Med. Oncol."},{"key":"68680_CR29","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1200\/JCO.19.00177","volume":"37","author":"AB Hont","year":"2019","unstructured":"Hont, A. B. et al. Immunotherapy of relapsed and refractory solid tumors with ex vivo expanded multi-tumor associated antigen specific cytotoxic T lymphocytes: a phase I study. J. Clin. Oncol. 37, 2349\u20132359 (2019).","journal-title":"J. Clin. Oncol."},{"key":"68680_CR30","doi-asserted-by":"publisher","first-page":"16168","DOI":"10.1073\/pnas.242600099","volume":"99","author":"C Yee","year":"2002","unstructured":"Yee, C. et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. 99, 16168\u201316173 (2002).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"68680_CR31","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1182\/blood.2023021979","volume":"143","author":"WK Leung","year":"2024","unstructured":"Leung, W. K. et al. Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia. Blood 143, 1726\u20131737 (2024).","journal-title":"Blood"},{"key":"68680_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/imm.12888","volume":"154","author":"M Collin","year":"2018","unstructured":"Collin, M. & Bigley, V. Human dendritic cell subsets: an update. Immunology 154, 3\u201320 (2018).","journal-title":"Immunology"},{"key":"68680_CR33","doi-asserted-by":"crossref","unstructured":"Mair, F. & Liechti, T. Comprehensive Phenotyping of Human Dendritic Cells and Monocytes. Cytometry. Part A: the journal of the International Society for Analytical Cytology 99, 231\u2013242 (2021).","DOI":"10.1002\/cyto.a.24269"},{"key":"68680_CR34","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415\u2013421 (2013).","journal-title":"Nature"},{"key":"68680_CR35","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.immuni.2019.08.012","volume":"51","author":"JG Abelin","year":"2019","unstructured":"Abelin, J. G. et al. Defining HLA-II ligand processing and binding rules with mass spectrometry enhances cancer epitope prediction. Immunity 51, 766\u2013779.e717 (2019).","journal-title":"Immunity"},{"key":"68680_CR36","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.immuni.2017.02.007","volume":"46","author":"JG Abelin","year":"2017","unstructured":"Abelin, J. G. et al. Mass spectrometry profiling of HLA-associated peptidomes in mono-allelic cells enables more accurate epitope prediction. Immunity 46, 315\u2013326 (2017).","journal-title":"Immunity"},{"key":"68680_CR37","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217\u2013221 (2017).","journal-title":"Nature"},{"key":"68680_CR38","doi-asserted-by":"crossref","unstructured":"Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222\u2013226 (2017).","DOI":"10.1038\/nature23003"},{"key":"68680_CR39","doi-asserted-by":"crossref","unstructured":"Dudley, M. E. et al. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J. Clin. Oncol. 31, 2152\u20132159 (2013).","DOI":"10.1200\/JCO.2012.46.6441"},{"key":"68680_CR40","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s00262-011-1004-8","volume":"60","author":"EME Verdegaal","year":"2011","unstructured":"Verdegaal, E. M. E. et al. Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha. Cancer Immunol., Immunother. 60, 953\u2013963 (2011).","journal-title":"Cancer Immunol., Immunother."},{"key":"68680_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46367-9","volume":"15","author":"JP Finnigan","year":"2024","unstructured":"Finnigan, J. P. et al. Structural basis for self-discrimination by neoantigen-specific TCRs. Nat. Commun. 15, 2140 (2024).","journal-title":"Nat. Commun."},{"key":"68680_CR42","doi-asserted-by":"crossref","unstructured":"Betts, M. R. et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J. Immunol. Methods 281, 65\u201378 (2003).","DOI":"10.1016\/S0022-1759(03)00265-5"},{"key":"68680_CR43","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1182\/blood.2021012714","volume":"139","author":"T Yoshikawa","year":"2022","unstructured":"Yoshikawa, T. et al. Genetic ablation of PRDM1 in antitumor T cells enhances therapeutic efficacy of adoptive immunotherapy. Blood 139, 2156\u20132172 (2022).","journal-title":"Blood"},{"key":"68680_CR44","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.3389\/fimmu.2019.02568","volume":"10","author":"YF Fuchs","year":"2019","unstructured":"Fuchs, Y. F. et al. Gene expression-based identification of antigen-responsive CD8(+) T cells on a single-cell level. Front Immunol. 10, 2568 (2019).","journal-title":"Front Immunol."},{"key":"68680_CR45","doi-asserted-by":"crossref","unstructured":"Borgers, J. S. W. et al. Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial. Nat. Med. 31, 881\u2013893 (2025).","DOI":"10.1038\/s41591-024-03418-4"},{"key":"68680_CR46","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.ccell.2022.03.012","volume":"40","author":"K-I Hanada","year":"2022","unstructured":"Hanada, K.-I. et al. A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers. Cancer Cell 40, 479\u2013493.e476 (2022).","journal-title":"Cancer Cell"},{"key":"68680_CR47","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.ccell.2022.03.005","volume":"40","author":"C Zheng","year":"2022","unstructured":"Zheng, C. et al. Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers. Cancer Cell 40, 410\u2013423.e417 (2022).","journal-title":"Cancer Cell"},{"key":"68680_CR48","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001136","volume":"9","author":"M Yang","year":"2021","unstructured":"Yang, M. et al. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer. J. Immunother. Cancer 9, e001136 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"68680_CR49","unstructured":"FDA. Manufacturing Changes and Comparability for Human Cellular and Gene Therapy Products (Guidance), 2023)."},{"key":"68680_CR50","doi-asserted-by":"crossref","unstructured":"Lee, K. H. et al. Ex vivo enrichment of PRAME antigen-specific T cells for adoptive immunotherapy using CD137 activation marker selection. Clin. Transl. Immunol. 9, e1200 (2020).","DOI":"10.1002\/cti2.1200"},{"key":"68680_CR51","doi-asserted-by":"publisher","first-page":"101049","DOI":"10.1016\/j.crmeth.2025.101049","volume":"5","author":"BP Conn","year":"2025","unstructured":"Conn, B. P. et al. Generation of T cell responses against broad KRAS hotspot neoantigens for cell therapy or TCR discovery. Cell Rep. Methods 5, 101049 (2025).","journal-title":"Cell Rep. Methods"},{"key":"68680_CR52","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/eji.201545849","volume":"46","author":"S Kelderman","year":"2016","unstructured":"Kelderman, S. et al. Antigen-specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapy. Eur. J. Immunol. 46, 1351\u20131360 (2016).","journal-title":"Eur. J. Immunol."},{"key":"68680_CR53","unstructured":"FDA. Guidance for FDA Reviewers and Sponsors - Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs)."},{"key":"68680_CR54","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/nprot.2012.037","volume":"7","author":"RS Andersen","year":"2012","unstructured":"Andersen, R. S. et al. Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers. Nat. Protoc. 7, 891\u2013902 (2012).","journal-title":"Nat. Protoc."},{"key":"68680_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1382-0","volume":"19","author":"FA Wolf","year":"2018","unstructured":"Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression data analysis. Genome Biol. 19, 15 (2018).","journal-title":"Genome Biol."},{"key":"68680_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-021-02577-8","volume":"23","author":"D Bredikhin","year":"2022","unstructured":"Bredikhin, D., Kats, I. & Stegle, O. MUON: multimodal omics analysis framework. Genome Biol. 23, 42 (2022).","journal-title":"Genome Biol."},{"key":"68680_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-020-02015-1","volume":"21","author":"R Argelaguet","year":"2020","unstructured":"Argelaguet, R. et al. MOFA+: a statistical framework for comprehensive integration of multi-modal single-cell data. Genome Biol. 21, 111 (2020).","journal-title":"Genome Biol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68680-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68680-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68680-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:06:33Z","timestamp":1776812793000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68680-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["68680"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-68680-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"5 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.S.W.B., and M.W.R. declare no competing interests. E.K.J., S.Hannes., C.G., S.M., K.N.B., A.P., M.R., J.Z.D., J.R.S., V.R.J., C.M.A., R.B.G., and M.M.v.B. are employees of BioNTech US or BioNTech SE. D.L., J.K., B.MC., M.N., E.E., K.S., J.H.F.S., J.A., Z.X., F.D.B., M.DM., K.M., and S. Hymson are former employees of BioNTech US or Neon Therapeutics. T.N.M.S. is a founder of Neon Therapeutics. D.L., J.K., B.MC., M.N., E.K.J., C.G.,\u00a0J.A., E.E., S.M., K.S., K.N.B. A.P., M.R., J.Z.D., J.R.S., V.R.J., C.M.A., M.DM., K.M., T.N.M.S., R.B.G., M.M.v.B. own stocks of BioNTech. N.A.M.B., R.D.B., M.V.Z., S.S., R.V., B.R., C.M.N., B.N. were under contract with BioNTech for drug product manufacturing. D.L., J.K., N.A.M.B., R.D.B., V.R.J., C.M.A., M.DM, T.N.M.S., J.H.v.d.B. and M.M.v.B. are inventors of patent applications that cover part of this article. NEO-STIM patents are pending in various countries (WO2020227546A1 and WO2019094642A1, - \u201cT cell manufacturing compositions and methods\u201d). J.B.H. received grant or research support from BioNTech US, Bristol Myers Squibb, Novartis AG, Amgen, Sastra Cell Therapy, Asher Bio. J.B.H. discloses ownership interest in Neogene Therapeutics. J.B.H. has an advisory role for Agenus, Astra Zeneca, Bristol Myers Squibb, CureVac, GSK, Imcyse, Iovance Bio, Immunocore, Ipsen, Merck Serono, MSD, Molecular Partners, Novartis, Orgenesis, Pfizer, Roche\/Genentech, Sanofi, Third Rock Ventures and is a Scientific Advisory Board (SAB) member at Achilles Tx, BioNTech US, Instil Bio, T-Knife, Neogene Therapeutics (AZ) and Sastra Cell Therapy. R.B.G is on the Board of Directors for Alkermes and Zai Lab and is a member of the SAB for Leap Therapeutics Inc. T.N.M.S. declares advisory roles for Allogene Therapeutics, Asher Bio, Merus, Neogene Therapeutics and Scenic Biotech, is stockholder in Allogene Therapeutics, Asher Therapeutics, Cell Control, Merus and Scenic Biotech, and is venture partner at Third Rock Ventures. BioNTech\u2019s role in the study is disclosed in the author contributions, none of the other organizations had a role in the study or publication.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3683"}}